Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
J. Clin. Oncol 2023 Mar 30;[EPub Ahead of Print], RE van Weelderen, K Klein, CJ Harrison, Y Jiang, J Abrahamsson, N Arad-Cohen, E Bart-Delabesse, B Buldini, B De Moerloose, MN Dworzak, S Elitzur, JM Fernández Navarro, RB Gerbing, BF Goemans, HA de Groot-Kruseman, E Guest, SY Ha, H Hasle, C Kelaidi, H Lapillonne, G Leverger, F Locatelli, R Masetti, T Miyamura, U Norén-Nyström, S Polychronopoulou, M Rasche, JE Rubnitz, J Stary, A Tierens, D Tomizawa, CM Zwaan, GJL KaspersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.